Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first‐in‐class, once‐daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873373/
https://www.ncbi.nlm.nih.gov/pubmed/29435979
http://dx.doi.org/10.1111/bjh.15058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873373/
https://www.ncbi.nlm.nih.gov/pubmed/29435979
http://dx.doi.org/10.1111/bjh.15058

Ejemplares similares